Idera Pharmaceutical (IDRA) 1.67 $IDRA Idera

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Idera Pharmaceutical (IDRA) 1.67 $IDRA

Idera Pharmaceuticals (IDRA) Catches Eye: Stock Rises 8.3%
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:41AM CDT
Idera Pharmaceuticals, Inc. (IDRA) shares rose over 8% in the last trading session.
IDRA: 1.67 (-0.05), ANIP: 61.06 (+0.46)

The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 5.82 (+0.02), BIIB: 301.83 (+11.90), IDRA: 1.67 (-0.05), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 5.82 (+0.02), BIIB: 301.83 (+11.90), IDRA: 1.67 (-0.05), RTRX: 18.17 (+0.24), LGND: 138.53 (+3.65), ACOR: 25.13 (-0.15)

Idera to Present at Two June Investor Healthcare Conferences
GlobeNewswire - Tue Jun 07, 8:00AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Medical Officer, Joanna Horobin, M.B., Ch.B. will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 4:00 p.m. Eastern Time at the Grand Hyatt in New York City.
IDRA: 1.67 (-0.05)

Idera reports 1Q loss
Automated Insights - Mon May 09, 3:45PM CDT
CAMBRIDGE, Mass. (AP) _ Idera Pharmaceuticals Inc. (IDRA) on Monday reported a loss of $12.8 million in its first quarter.
IDRA: 1.67 (-0.05)

Idera Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Mon May 09, 3:00PM CDT
9 of 10 Waldenstrom's Macroglobulinemia Patients Treated at the Highest Dose have Demonstrated Reductions in IgM or M-Protein Levels in Ongoing Trial
IDRA: 1.67 (-0.05)

Idera to Release 2016 First Quarter Results on May 9, 2016
GlobeNewswire - Thu May 05, 6:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced that first quarter results for 2016 are expected to be released on Monday, May 9, 2016 after the close of the U.S. Financial Markets.
IDRA: 1.67 (-0.05)

Idera Presents Preclinical Data Demonstrating Enhanced Systemic Anti-Tumor Activity from Combination Treatment with Intra-tumoral IMO-2125 and IDO-1 Inhibitor at AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 6:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced new preclinical data demonstrating enhanced systemic anti-tumor activity in preclinical cancer models with intra-tumoral administration of IMO-2125 in combination with an inhibitor of the immunosuppressive enzyme, indoleamine-pyrrole 2,3-dioxygenase (IDO1). IMO-2125 is a synthetic oligonucleotide-based agonist of Toll-like receptor 9 discovered and developed by Idera. IDO is one of several immune checkpoints involved in tumor immune escape. IDO-1 inhibitors are currently in clinical development. These data are being presented at the AACR Annual Meeting 2016 in New Orleans, LA.
IDRA: 1.67 (-0.05)

Idera to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 11, 9:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Executive Officer, Vincent Milano will present at the 15 Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 3:40 p.m. Eastern Time at the Westin Grand Central Hotel in New York City.
IDRA: 1.67 (-0.05)

Global Idera Pharmaceuticals, Inc. Market Overview Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 5:13AM CST
'IDERA PHARMACEUTICALS, INC. - Product Pipeline Review - 2015', provides an overview of the IDERA PHARMACEUTICALS, INC.'s pharmaceutical research and development focus.
IDRA: 1.67 (-0.05)

Diffuse Large B-Cell Lymphoma Therapeutics Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgllc/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diffuse Large B-Cell Lymphoma Overview - Therapeutics Development - Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview - Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis - Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies - Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diffuse Large B-Cell Lymphoma - Products under Development by Companies - Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BeiGene(Beijing) Co.,Ltd - BIND Therapeutics, Inc. - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - Curis, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Inflection Biosciences Limited For more information visit http://www.researchandmarkets.com/research/kw...fuse_large
CRIS: 1.74 (+0.06), IMMU: 2.80 (+0.15), INCY: 90.00 (-0.21), IMGN: 2.96 (+0.18), AMGN: 174.16 (+2.13), EPZM: 10.35 (-0.01), BIND: 0.78 (-0.09), GSK: 45.25 (+0.18), BMY: 76.19 (+1.38), CTIC: 0.34 (unch), IDRA: 1.67 (-0.05), CYCC: 5.01 (-0.02), GILD: 80.46 (+0.99), AZN: 33.84 (-0.30), ABBV: 66.94 (+0.71), CBMG: 14.82 (-0.07), CELGZ: 1.14 (-0.02)

Global Moderate Psoriasis Therapeutics Development Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/svzcsv/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Moderate Psoriasis Overview - Therapeutics Development - Pipeline Products for Moderate Psoriasis - Overview - Pipeline Products for Moderate Psoriasis - Comparative Analysis - Moderate Psoriasis - Therapeutics under Development by Companies - Moderate Psoriasis - Therapeutics under Investigation by Universities/Institutes - Moderate Psoriasis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Moderate Psoriasis - Products under Development by Companies - Moderate Psoriasis - Products under Investigation by Universities/Institutes - Moderate Psoriasis - Companies Involved in Therapeutics Development - AbGenomics International, Inc. - ADC Therapeutics Sarl - Almirall, S.A. - AstraZeneca Plc - Avexxin AS - Boehringer Ingelheim GmbH - Celgene Corporation - Convoy Therapeutics, Inc. - Crescendo Biologics Limited - Delenex Therapeutics AG - Eli Lilly and Company - Forward Pharma A/S - Galectin Therapeutics, Inc. - GlycoMar Limited - Idera Pharmaceuticals, Inc. - Johnson & Johnson - Merck KGaA - OPKO Health, Inc. - Sandoz International GmbH - Soligenix, Inc. - Sun Pharma Advanced Research Company Ltd. - Syntrix Biosystems, Inc. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/svzcsv/moderate
JNJ: 125.40 (+0.17), IDRA: 1.67 (-0.05), OPK: 10.07 (+0.12), FWP: 19.40 (-0.67), AZN: 33.84 (-0.30), GALT: 1.92 (+0.28), LLY: 83.18 (+0.29), VRX.TO: 29.08 (-1.37), CELGZ: 1.14 (-0.02)

Waldenstrom Macroglobulinemia Therapeutics Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/v6dn7v/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Waldenstrom Macroglobulinemia Overview - Therapeutics Development - Pipeline Products for Waldenstrom Macroglobulinemia - Overview - Pipeline Products for Waldenstrom Macroglobulinemia - Comparative Analysis - Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies - Waldenstrom Macroglobulinemia - Therapeutics under Investigation by Universities/Institutes - Waldenstrom Macroglobulinemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Waldenstrom Macroglobulinemia - Products under Development by Companies - Waldenstrom Macroglobulinemia - Products under Investigation by Universities/Institutes - Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - BeiGene(Beijing) Co.,Ltd - Calithera Biosciences, Inc. - Celgene Corporation - Genentech, Inc. - Genmab A/S - Gilead Sciences, Inc. - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - IGF Oncology, LLC. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v6...aldenstrom
INCY: 90.00 (-0.21), IDRA: 1.67 (-0.05), GILD: 80.46 (+0.99), CALA: 3.15 (-0.02), ABBV: 66.94 (+0.71), NVS: 83.07 (-0.19), CELGZ: 1.14 (-0.02), KPTI: 7.23 (-0.15)

Forget Inovio Pharmaceuticals, Inc.: These 2 Stocks Are Better Buys
Keith Speights, The Motley Fool - Motley Fool - Tue Jan 26, 3:40PM CST
Image Source: Inovio Pharmaceuticals. Sure, the future for the DNA immunotherapies under development by Inovio Pharmaceuticals (NASDAQ: INO) seems very promising. But after a year when Inovio's shares dropped nearly 28%, some investors might be...
INO: 10.42 (+0.54), CARA: 6.04 (+0.11), IDRA: 1.67 (-0.05), AZN: 33.84 (-0.30)

Why Shares in Idera Pharmaceuticals, Inc. Dropped 10% Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Jan 15, 2:51PM CST
Image source: Idera Pharmaceuticals. W hat: After presenting at the J.P. Morgan healthcare conference on Wednesday and hitting a new 52-week low yesterday, shares in Idera Pharmaceuticals   slumped by another 10% earlier today. So what: The...
IDRA: 1.67 (-0.05)

Why Idera Pharmaceuticals Inc. Shares Dropped 36% in 2015
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jan 13, 6:18AM CST
What: Shareholders of Idera Pharmaceuticals , a clinical-stage biopharmaceutical company focused on cancer and other rare diseases, had a rough 2015. The company's shares lost more than 36% of their value in during the year, according to data from...
IDRA: 1.67 (-0.05), GSK: 45.25 (+0.18)

3 Biotech Stocks to Buy in January
Brian Feroldi, Keith Speights, and Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jan 12, 6:03AM CST
Image source: TBIT via Pixabay. Biotech stocks are off to a rough start in 2016. Several of the most popular exchange-traded funds that focus on the industry have been sold off since the start of the year, with one down by more than 8% in only the...
MDVN: 64.08 (+0.09), IDRA: 1.67 (-0.05), FGEN: 19.73 (+0.60)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 124

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 131

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 189

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 67

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 19

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
XKIG Bolsters Northwest with Jensen's Acquisition

Updated Category News Views 29

Stepping Up the Game in the Pacific Northwest Well, here we see another classic example of a shrewd move in the infrastructure sector. XKIG, a name known to those who keep an eye on critical infrastructure services for utilities, has decided to widen its footprint with a strategic grab of Jensen's Tree Service, Inc. They’re setting up shop even deeper in the Pacific...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 55

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 81

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 107

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 33

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Unique Features of Ontomir (OTM) on BitMart

Updated Category News Views 315

Ontomir (OTM) Launches on BitMart Exchange In the world of digital assets, BitMart, a leading global trading platform, has recently showcased its commitment to innovation by announcing the listing of Ontomir (OTM). This launch marks a significant milestone for Ontomir, as the OTM/USDT trading pair becomes available, creating new opportunities for investors. Understanding...

Continue Reading
Vanguard Introduces New Actively Managed Bond ETF for Investors

Updated Category News Views 199

Vanguard Unveils a New Actively Managed Bond ETF Today, Vanguard has proudly introduced the Vanguard Multi-Sector Income Bond ETF (VGMS), a new offering in the realm of actively managed fixed-income exchange-traded funds (ETFs). This innovative product is supervised by the Vanguard Fixed Income Group, known for its extensive expertise in the field. A Commitment to...

Continue Reading
U.S. Markets Experience Mixed Trading Amid Oil Inventory Declines

Updated Category News Views 95

Mixed Performance of U.S. Stocks U.S. stocks displayed a mixed performance during the mid-week trading session, with the S&P 500 edging slightly lower. The markets reacted to various financial reports and inventory levels that influenced trader sentiments. Index Updates The Dow Jones recorded a modest increase, up by 0.08% to 42,267.94. In contrast, the NASDAQ saw a...

Continue Reading
Alignment Healthcare's Strategic Presentation Insights

Updated Category News Views 162

Alignment Healthcare's Upcoming Presentation Alignment Healthcare, Inc. (NASDAQ: ALHC) is making waves in the healthcare sector as it gears up for an important presentation at a renowned healthcare conference. This significant event will take place in January, showcasing the company's commitment to transforming senior care. The Conference Details On January 15, 2025, at...

Continue Reading
Unveiling Talen Energy's Options Trading Trends and Insights

Updated Category News Views 185

Insights into Talen Energy's Recent Options Activity Whales, those significant players in the financial markets, have recently shown a strong bullish interest in Talen Energy. This interest is reflected in a notable increase in options trading activity regarding Talen Energy (NASDAQ: TLN). Understanding the Trading Trends for TLN Within the recent options trading history...

Continue Reading